Susan Catalano, PhD, of Cognition Therapeutics Inc., Pittsburgh, PA, discusses the recent study investigating how the A673T mutation confers its Alzheimer’s disease protection. The A673T mutation is the strongest protective mutation found to date, this amyloid precursor protein (APP) molecule mutation makes carriers 4-times less likely to develop Alzheimer’s disease than non-carriers. Results from the study indicate the amyloid-β (Aβ) oligomers formed under the A673T mutation bind with a four-fold lower affinity to synapses than do normal oligomers. This suggests that therapeutics that effectively reduce oligomer binding to synapses in the brain may be beneficial in Alzheimer’s disease. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).